Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. / Edvardsson, Bengt.

I: SpringerPlus, Vol. 2, Nr. Sep 22, 479, 2013.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.

AU - Edvardsson, Bengt

PY - 2013

Y1 - 2013

N2 - Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day.

AB - Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day.

U2 - 10.1186/2193-1801-2-479

DO - 10.1186/2193-1801-2-479

M3 - Article

VL - 2

JO - SpringerPlus

T2 - SpringerPlus

JF - SpringerPlus

SN - 2193-1801

IS - Sep 22

M1 - 479

ER -